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SObjective:Minimally invasive thymectomy for stage I to stage II thymoma has been suggested in recent years
and considered technically feasible. However, because of the lack of data on long-term results, controversies still
exist on surgical access indication. We sought to evaluate the results after robot-assisted thoracoscopic thymec-
tomy in early-stage thymoma.
Methods: Data were collected from 4 European centers. Between 2002 and 2011, 79 patients (38 men and
41 women; median age, 57 years) with early-stage thymoma were operated by left-sided (82.4%), right-
sided (12.6%), or bilateral (5%) robotic thoracoscopic approach. Forty-five patients (57%) had associated
myasthenia gravis.
Results:Average operative timewas 155 minutes (range, 70-320 minutes). One patient needed open conversion,
in 1 patient a standard thoracoscopy was performed after robotic system breakdown, and in 5 patients an addi-
tional access was required. No vascular and nervous injuries were recorded, and no perioperative mortality oc-
curred. Ten patients (12.7%) had postoperative complications. Median hospital stay was 3 days (range, 2-15
days). Median diameter of tumor resected was 3 cm (range, 1-12 cm), and Masaoka stage was stage I in 30 pa-
tients (38%) and stage II in 49 patients (62%). At a median follow-up of 40 months, 74 patients were alive and 5
had died (4 patients from nonthymoma-related causes and 1 from a diffuse intrathoracic recurrence), with
a 5-year survival rate of 90%.
Conclusions: Our data indicate that robot-enhanced thoracoscopic thymectomy for early-stage thymoma is
a technically sound and safe procedure with a low complication rate and a short hospital stay. Oncologic out-
come seems good, but a longer follow-up is needed to consider this as a standard approach definitively. (J Thorac
Cardiovasc Surg 2012;144:1125-32)Thymoma is the most common primary tumor in the ante-
rior mediastinum of adults. A complete surgical resection
with safety margins is considered curative for resectable tu-
mors and represents the most important prognostic factor.1
During the past 2 decades, video-assisted thoracoscopic sur-
gery (VATS) has been performed frequently for the treat-
ment of mediastinal benign diseases or for thymectomy in
cases of nonthymomatous myasthenia gravis (MG).2,3
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The Journal of Thoracic and Carby a median sternotomy has been universally accepted as
the standard treatment.4 The VATS approach for thymoma
remains controversial, and many surgeons are reluctant to
use this technique because of the supposed increased risk
of local recurrence, reduced safety margins after minimally
invasive resection, possible rupture of the capsule, and seed-
ing of the tumor during endoscopic manipulations. Further-
more, the lack of long-term data on survival and oncologic
results, and the difficult learning curve for performing the
operation are additional reasons to support any doubts
regarding the effectiveness of VATS resection for early-
stage thymomas.5 The introduction of robotic-assisted tech-
nologies during the late 1990s provided a technical
improvement that overcame the limitations of conventional
thoracoscopy. In fact, the 3-dimensional vision system and
the multiarticulated instruments of the da Vinci Surgical
Robotic System (Intuitive Surgical, Inc, Sunnyvale, Calif)
have added further precision and dexterity. This technology
has been tested in a variety of thoracic surgery procedures,
with clear evidence that the robotic system provides its best
advantage when operating in tiny and difficult-to-reach an-
atomic regions such as the mediastinum. Therefore, medias-
tinal diseases were selected electively by most surgeons for
clinical research using the da Vinci robot.6,7 The aim of thisdiovascular Surgery c Volume 144, Number 5 1125
Abbreviations and Acronyms
MG ¼ myasthenia gravis
VATS ¼ video-assisted thoracoscopic surgery
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Sstudy was to evaluate the safety and feasibility of robotic
thymectomy by analyzing the oncologic outcomes in
a group of patients affected by early-stage thymoma and op-
erated on in 4 European Centers with significant experience
in this kind of operation.MATERIALS AND METHODS
We reviewed the data of 79 patients undergoing robotic thymectomy for
clinically defined early-stage thymoma (Masaoka stages I and II) collected
between February 2002 and March 2011 by 4 European Thoracic Surgery
Centers (University of Berlin, Germany, 39 patients; University of Padova,
Italy, 14 patients; University of Pisa, Italy, 13 patients; University of Inns-
bruck, Austria, 13 patients). All patients signed a detailed consent form in
which theywere informed about possible complications of thymoma resec-
tion by the robotic thoracoscopic approach and the lack of long-term data.
The institutional review board of each center approved this study. Informa-
tion on patient demographics, presence of associatedMG, tumor character-
istics, stage, intra- and postoperative data (eg, complications, need for open
conversion or additional ports or accesses, operative time, length of hospi-
tal stay), and administration of adjuvant treatment were collected. The Ma-
saoka staging system was used to assess the pathological stage,8 whereas
the new World Health Organization classification was used for defining
the histology.9 The Myasthenia Gravis Foundation of America classifica-
tion10 was applied to stratify the preoperative class of MG. Preoperative as-
sessments included an evaluation of pulmonary and cardiac function, and
total body computed tomography or magnetic resonance imaging. Pre-
ferred radiologic characteristics to be eligible for robotic thymectomy
were as follows: location of the tumor in the anterior mediastinum; a dis-
tinct fat plane between the tumor and surrounding structures; unilateral
tumor predominance; tumor encapsulation; existence of residual, normal-
appearing thymic tissue; and no mass compression effect (Figure 1).11
Tumor size was not considered a strict selection criterion; however, a diam-
eter5 cmwas preferred; an evident unilateral predominancewas essential
to start the robotic procedure for tumors>5 cm. Exclusion criteria were ra-
diologic evidence of invasion of surrounding structures (eg, pericardium,
lung, nerves, or large vessels), the presence of adhesions (eg, previous tho-
racic surgery or pleuritis), the inability to perform single-lung ventilation,
or a body mass index>35. All patients completed the follow-up (the last
follow-up was March 2012) with a periodic clinical evaluation. Chest
and abdominal computed tomographic scans were required every 6 months
during the first 2 years after surgery, and then every year. Patients with MG
were also evaluated periodically by the referring neurologists and were sent
for surgical evaluation in case of worsening MG symptoms.
Surgical Technique
A 3- or 4-arm da Vinci robotic system was used. Briefly, the general
setup was as follows. The patient was positioned left side up at a 30 angle
using a bean bag. A camera port for the 3-dimensional 0 stereo-endoscope
was introduced through a 15-mm incision in the fifth intercostal space on
the midaxillary line. Care was taken when operating on the left side to
avoid the heart, which lies just beneath this area. Thus, under camera vision
and carbon dioxide insufflation to turn away the heart, 2 additional thoracic
ports were inserted: one in the third intercostal space on the midaxillary
line and another in the fifth intercostal space between the parasternal and
the midclavicular lines (Figure 2). The robotic thymectomy surgical1126 The Journal of Thoracic and Cardiovascular Surtechnique either from the left or right side has been described previ-
ously.12,13 We emphasize some technical tips and pitfalls. Unlike the
thoracoscopic approach for a nonthymomatous gland, some oncologic
modifications were adopted in the case of a thymoma resection. All
surgeons involved adopted a ‘‘no-touch technique’’ with an en-bloc resec-
tion of the thymus and perithymic fat tissue. During this technique, the thy-
moma was never touched, and normal thymic tissue and perithymic fat
were used for grasping and for traction, to avoid direct manipulation of
the tumor, capsular damage, and potential seeding. All thymic and perithy-
mic fat was dissected with safe surgical margins, according to the Interna-
tional Thymic Malignancy Interest Group criteria,14 and the completeness
of the thymectomy was assessed by macroscopic inspection of the thymic
bed and the specimen (Figure 3). Either a spatula, hook monopolar coagu-
lators, or an ultrasonic dissector were used routinely for dissection, focus-
ing on avoiding thermal injury particularly when operating close to the
phrenic nerves. Carbon dioxide insufflation of 8 to 12 mm Hg was applied
during the procedure to increase the size of the mediastinal space.
Statistical Analysis
Data are expressed as median or mean  standard deviation. The nor-
mality of the quantitative variable distribution was verified by the
Shapiro-Wilk test. The Student t test for paired data or Wilcoxon signed-
rank test was used, as appropriate, to evaluate differences between
means. Survival curves were calculated by the Kaplan-Meier method. A
P value< .05 was considered to indicate statistical significance.RESULTS
Thirty-eight men (48.1%) and 41 women (51.9%) were
enrolled, with a median age of 57 years (range, 13-84
years). Forty-five patients (56.9%) were affected by MG.
Preoperative Myasthenia Gravis Foundation of America
class was I in 9 patients, IIA in 4 patients, IIB in 11 patients,
IIIA in 11 patients, IIIB in 7 patients, IVA in 2 patients, and
IVB in 1 patient. The robotic thoracoscopic surgical ap-
proach was left-sided in 65 patients (82.3%), right-sided
in 10 patients (12.6%), and bilateral in 4 patients (5.1%).
Median operative time was 155 minutes, (range, 70-320
minutes; mean, 165  52 minutes). One patient (1.3%) re-
quired conversion to an open approach because of a large-
diameter tumor interfering with a safe dissection. One
patients (1.3%) required a standard thoracoscopy after the
robotic system broke down. Five patients (6.3%) needed
additional access (cervicotomy in 1 patients as a result of
a difficult dissection plane in the neck independent from
the tumor, and an additional omolateral thoracoscopic
port for suction purposes in 4 patients). No vascular or nerve
injuries were recorded and no perioperative mortality oc-
curred. Ten patients (12.7%) had postoperative complica-
tions: 1 pneumothorax treated with a chest tube, 1
hemothorax treated conservatively with a blood transfusion,
3 pleural effusions, 1 case of pneumonia, 1 case of ortho-
static hypotension, 1 atrial fibrillation, 1 wound infection,
and 1 urinary tract infection treated with medical therapy.
Median hospital stay was 3 days (range, 2-15 days; mean,
4.4  2.5 days). Median time to chest drainage removal
was 2 days (range, 1-8 days; mean, 2.4 1.6 days). Median
diameter of the resected tumors was 3 cm (range, 1-12 cm;gery c November 2012
FIGURE 1. Computed tomographic scan of an early-stage thymoma.
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Smean, 3.7  2 cm). Masaoka stage was I in 30 patients
(38%) and II in 49 patients (62%). World Health Organiza-
tion histology was type A in 14 patients (17.7%), AB in 22
patients (27.8%), B1 in 12 patients (15.2%), B2 in 18 pa-
tients (22.8%), B3 in 12 patients (15.2%) and C in 1 patient
(1.3%). No relationship was found between tumor diameter
and Masaoka stage (stage I mean diameter, 3.6  2.1 cm;
stage II mean diameter, 3.7  1.9 cm; P ¼ .88), and no sig-
nificant difference in operative time was seen when operat-
ing on tumors with dimensions>3 cm (mean operative time
for tumors 3 cm 155  49 minutes vs 175  53 minutes
for tumors>3 cm; P¼ .10). Postoperative radiation therapy
was administered in 18 cases, all with stage II disease. At
the last follow-up (median, 40 months; range, 12-121FIGURE 2. A, In the surgical room, the patient is positioned supine on the surgi
to expose the axillary region. The da Vinci robotic systemwith the surgical cart a
intercostal spaces (sites of incisions for port placement) are identified. The thor
ports and are operative (D). Conflict between arms should be avoided.
The Journal of Thoracic and Carmonths; mean, 51.7  33 months), 74 patients were alive,
4 patients had died of nonthymoma-related causes (leuke-
mia, vulvar carcinoma, pneumonia, and sepsis), and 1 pa-
tient (type C, 5-cm tumor) died because of a diffuse
intrathoracic recurrence. The 5-year overall survival rate
was 90% (Figure 4, A); the 5-year thymoma-related
survival was 97% (Figure 4, B).DISCUSSION
In a systematic review, Davenport and colleagues15 re-
ported an overall 5-year survival rate for patients with Ma-
saoka stage I and stage II thymoma, after complete surgical
resection, ranging from 89% to 100% and 71% to 95%,
respectively. The authors pointed out the lack of evidence
in the current literature supporting a minimally invasive
approach compared with a standard transsternal approach.
In particular, few authors have reviewed systematically
the surgical results of thoracoscopic (conventional or
robot-assisted) thymectomy for early-stage thymoma
(Table 11,2,11,16-20). The available data were sufficient to
confirm only that this approach could be considered
technically sound and safe in the hands of appropriately
trained surgeons. However, data were inconclusive with
regard to oncologic outcome, which was primarily the
result of the long (10-year) lapse of time necessary in pa-
tients with thymoma to evaluate the survival and relapse
rate. At that time, the open transsternal surgical approach
was widely considered the gold standard for resectingcal table with the left side elevated at 30. The left arm is flexed on a support
nd the surgeon’s console are displaced. B, Before surgery the fifth and third
acic ports are placed, (C) and the arms of the robot are then attached to the
diovascular Surgery c Volume 144, Number 5 1127
FIGURE 3. A, Intraoperative left thoracoscopic view of an encapsulated thymoma (white arrow). B, Specimen after thymectomy.
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section.1,4 VATS was introduced in clinical practice during
the early 1990s and soon gained broad acceptance for
diagnostic and therapeutic interventions for benign
mediastinal diseases.2,3 The advantages of this minimally
invasive approach have resulted in greater acceptability,
particularly among patients with MG, leading to an
increased number of thoracoscopic thymectomies being
performed for nonthymomatous MG with good surgical
and neurologic results.12,13 However, most surgeons are
still reluctant to undertake a thoracoscopic-assisted thymec-
tomy in patients with thymoma because of technical and
oncologic concerns.Technical Aspects
The upper mediastinum is a delicate and difficult-to-
reach anatomic area for thoracoscopy, with large, vulner-
able vessels and nerves. The 2-dimensional view of the
operative field, the surgeon’s tremor enhanced by the
thoracoscopic instruments, and the fact that the instru-
ments do not articulate make it difficult to operate in
a fixed, tiny 3-dimensional space such as the mediasti-
num. Moreover, thoracoscopic thymectomy is considered
a technically challenging operation that requires a long
learning curve.5 The introduction of robotic surgical
systems added a new dimension to conventionalFIGURE 4. A, Overall survival. B
1128 The Journal of Thoracic and Cardiovascular Surthoracoscopy, providing additional advantages and over-
coming some technical and methodological limits. First,
the improved dexterity of instruments that can articulate
with 7 of freedom and rotate 360 allows complex
3-dimensional movements superior to those permitted
by conventional minimally invasive instruments, enhances
dissection safety around vessels and nerves, and is more
comfortable in tiny, remote areas such as the superior
horns or the contralateral mediastinum. Second, the
high-resolution, 3-dimensional real-time video image per-
mits the best possible and magnified view of the surgical
field. Third, the filtering of hand tremors allows greater
technical precision.
In our series, our preference was for a left-sided approach
for technical, clinical, and anatomic reasons. As demon-
strated by R€uckert and associates,21 the larger part of the
thymus is on the left side. Furthermore, in about 72% of pa-
tients22 the thymus gland is located lateral and under the left
phrenic nerve, which is better identified and dissected safely
under direct vision from the left. The right phrenic nerve is
protected partially by the superior vena cava in the high me-
diastinum and may be identified and followed easily in the
lower part. For patients with MG, all mediastinal fat tissue
was removed, comprising an aortopulmonary window,
which is a frequent side of ectopic thymic tissue, and it is
easier to reach by the left-sided approach. The right-sided, Thymoma-related survival.
gery c November 2012
TABLE 1. Review of the published studies on thoracoscopic thymectomy for early-stage thymoma
Authors
No. of
patients SA
Masaoka
stage I/II TS, cm
5-Year
survival,% Follow-up, mo RR,% OC,%
OT,
minutes
POS,
days
Roviaro and colleagues2 22 uVATS 22 — — — 4.5 4.5 75* 6*
Cheng and colleagues11 44 uVATS 27/17 7.7* 100 34.6* 0 0 194* 7.6*
Odaka and colleagues16 22 uVATS — — — 21.6* 0 0 194* 4.6*
Agasthian and Lin17 50 uVATS 25/25 5* 100 58* 2 0 150* 5*
Pennathur and colleagues18 18 bVATS 5/13 3.5* 100 27y 0 0 - 2.9*
Takeo and colleagues19 34 bVATS 15/19 5.2* 100 65* 2.8 0 219* 10.5*
Mussi and colleagues20 13 Robotic 7/6 3.3* 100 14.5y 0 7.7 139* 4*
Current series 79 Robotic 30/49 3.7* 90 51.7* 1.3 1.3 165* 4.4*
SA, Surgical access; TS, tumor size; RR, recurrence rate; OC, open conversion; OT, operative time; POS, postoperative length of stay; uVATS, unilateral video-assisted thoracic
surgery; bVATS, bilateral video-assisted thoracic surgery. *Mean value. yMedian value.
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right side.
Safety
The main oncologic concern is related to possible breach
of the tumor capsule, with risk of tumor seeding locally or in
the pleural cavity, and the difficult evaluation of resection
margins with reduced oncologic accuracy and safety. In
our opinion, the robotic approach has some clear advan-
tages compared with conventional thoracoscopy. In fact,
a lesser manipulation of the thymic and perithymic tissue
is required during the operation, and a better evaluation of
healthy tissue as a result of the high-quality images leads
to a more precise and low-risk dissection, with wide safety
margins and reduced possibility of tumor breaching, incom-
plete resection, or iatrogenic injury. The use of carbon diox-
ide inflation (usually 8-12 mm Hg) during the operation is
another advantage, which allows enlargement of the medi-
astinal space with better visualization. The lack of tactile
feedback could, theoretically, increase the risk of damaging
tumor tissue; however, this disadvantage seems compen-
sated for by the superior 3-dimensional vision control of
the system. No complications based on a lack of tactile
feedback were observed in our series. The completeness
of the procedure was proved by intraoperative evaluation
of the resection margins, back-table investigation of the
specimens, and the histological analysis.
Surgical and Oncologic Results
Different from other authors,16,23 we support
a thoracoscopic subtotal thymectomy for noninvasive
thymoma without MG as the preferred resection modality,
regardless of tumor size or the nature of its surrounding
capsule. Our policy was to undertake an extended
thymectomy in all cases, such as in an open approach. In
the absence of definitive long-term data standardization of
the technique, it is necessary to avoid biases during outcome
evaluations. Moreover, we consider the intraoperative ma-
nipulation of the specimen safer when the perithymic fat tis-
sue is contextually resected en bloc. A further debated pointThe Journal of Thoracic and Caris the appropriate size of thymoma for VATS or robotic re-
section. The majority of the literature considers lesions 5
cm, but an average-size tumor of 3 cm is generally consid-
ered acceptable oncologically.5 In our experience, the me-
dian diameter of resected lesions was 3 cm, with a range of
1 to 12 cm. Large tumor size was not considered an absolute
contraindication; however, it may interferewith the thoraco-
scopic procedure, because themanipulation ismore difficult,
with an increased chance of an open conversion, or it may
prolong operative time. In fact, the single case requiring an
open conversion in our series was a 6-cm-diameter tumor
inwhich themanipulationwas considereda risk.As ageneral
rule, we follow the radiologic criteria proposed by Cheng
and coworkers11 to select candidates for thoracoscopic thy-
mectomy in patients with thymoma: location in the anterior
mediastinum; tumor encapsulation; a distinct fat plane be-
tween the tumor and vital organs; the existence of residual,
normal-appearing thymic tissue; no mass compression ef-
fect; and unilateral tumor predominance, particularly for tu-
mors 3 cm. However, despite that most cases in our series
were diagnosed clinically as Masaoka stage I, 49 patients
(62%) were Masaoka stage II after histologic evaluation.
A similar finding was reported by Takeo and colleagues,19
with 57% of their patients as Masaoka stage II and stage
III after an initial clinical diagnosis of stage I,whereas in a re-
port by Quintanilla-Martinez and associates,24 28.5% of the
tumors reported to be encapsulated by the surgeon showed
microscopic evidence of capsular invasion. No relationship
was found between the size of the tumor and Masaoka stage
in our series; therefore, a greater size did not predict an in-
creased stage.Our surgical resultswere goodwith nomortal-
ity, low morbidity, and short hospital stays. The operative
timewas comparable with other series of thoracoscopic thy-
moma resection reported in Table 1, but was slightly higher
compared with thymectomy for nonthymomatous MG.12,13
The learning curve for the no-touch technique and the
more complex and accurate dissection required in these
cases could explain these results. The open conversion rate
was also low (1.3%) and comparable with that reported in
the literature (range, 0%-7.7%). With regard to oncologicdiovascular Surgery c Volume 144, Number 5 1129
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in a thoracoscopic series (Table 1) with variable follow-up
(14.5-65 months). Our data agree with the 1.3% recurrence
rate; the single relapse observed was in a type-C thymic tu-
mor, the histology of which was defined only after surgery.
No clear evidence of a violation of oncologic principles dur-
ing the surgical procedure was recorded in this patient. De-
spite adjuvant treatment, the patient developed a diffuse
intrathoracic recurrence, surviving 52months after the oper-
ation. Cheng and coworkers25 and Pennathur and col-
leagues18 compared VATS and transsternal approaches for
thymoma in a small series and reported no significant differ-
ence in recurrence rate or overall survival between the 2
groups. Although encouraging, these results cannot be con-
sidered definitive, because the indolent nature of thymoma
requires longer follow-up data, such as 10 years, to deter-
mine the oncologic outcome of thoracoscopic thymectomy.
The current study had some limitations—in particular, its
nonrandomized, retrospective, and multi-institutional de-
sign. In addition, although the follow-up was longer than
that of most previous studies, it was still inadequate to allow
a definitive conclusion on oncologic outcome. In summary,
robotic-assisted thoracoscopic thymectomy for early-stage
thymomas can be performed safely and efficiently from
a technical point of view. In addition to the advantages of
the minimally invasive approach (short hospital length of
stay, excellent cosmetics, and low morbidity), the increased
visualization and instrument dexterity afforded by robotic
technology provides further benefit over conventional thor-
acoscopy. Our data on a relatively large number of patients
are encouraging; however, thymoma resection with conven-
tional or robot-assisted thoracoscopy remains under evalu-
ation, because long-term oncologic results are lacking.References
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outstanding results. I appreciate receiving the manuscript for my
timely review.
Dr Marulli and his colleagues have described an early analysis
of a large series of patients with early-stage thymoma treated with
robotic thymectomy with excellent perioperative results from 4
large centers. The operating room times were quite reasonable,
complications low and reasonable and not really related to the ap-
proach, the median length of stay was short at 3 days, and the re-
currence rate observed was quite low. The one caveat of the series
is that the median follow-up is relatively short at 3.5 years. There’s
no question that there was very careful and prudent case selection,
and prudent and careful intraoperative operating room judgment
exercised, with a no-touch and en bloc technique as well as with
total thymectomy. An important caveat is that most recurrences
of encapsulated early-stage thymomas occur between 5 years
and 10 years in all the series that have been reported to date. Ob-
viously, your follow-up is short and, as you appropriately say, your
conclusions are tentative at this point; however, I expect the resultsgery c November 2012
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Sin the end to be equivalent to the open approach, and I look forward
to your publication in another 5 to 10 years describing those results
with your excellent judgment and excellent technical skills.
I have just a couple of comments. Just to confirm, because it
wasn’t described in your paper, were, indeed, all resections an
R0 resection?
Dr Marulli. In our opinion, the resections were all R0 resec-
tions. All the specimens were evaluated macroscopically and mi-
croscopically after resection.
DrWright. You didn’t describe in your manuscript the method
of follow-up, and obviously clinical follow-up by calling their phy-
sician, a telephone call to the patient, or a chest radiograph are all
inadequate. The only follow-up that is really adequate for patients
with thymoma is periodic computed tomography (CT) scans to
look at the mediastinum and the pleural space. Did all of your pa-
tients have follow-up CT scans, what was the follow-up protocol,
and were there any patients lost to follow-up or not put on a CT
periodic surveillance protocol?
Dr Marulli. Obviously, these patients were carefully followed
up. Usually, our protocol is to do a clinical in-hospital evaluation
of the patient at least every 6 months during the first 3 years,
with a CT scan at least every year.Moreover, regarding the patients
with MG, all these patients are followed up by a team of neurolo-
gists who have a close connection with us, and then in case of var-
iation of clinical status, like a worsening of MG, they are referred
to us to evaluate the possible presence of a recurrence. But in all
patients, we do a CT scan at least each year.
Dr Joseph B. Shrager (Stanford, Calif). So all of these patients
had a CT scan?
Dr Marulli. Yes.
Dr Shrager. Within a year of the study data collection?
Dr Marulli. Yes. The last follow-up was last March.
Dr Wright. The last query is the patient who had a diffuse in-
trathoracic recurrence. It makesme concerned that therewas a cap-
sular violation. I realize it was a type C patient, but in looking
back, were there reasons why that patient would recur diffusely in-
trathoracically so early?
DrMarulli. This patient was in the group at Innsbruck and was
not a stage I but was a stage IIB patient. We asked to reevaluate the
histology of this patient, but I have no reply at this moment. It is
possible that the capsule was breached. The patient did adjuvant
radiotherapy, but he relapsed intrathoracically with both pleural
and intrapulmonary metastases. I don’t know if the patient is really
type C, but we are evaluating that.
Dr Wright. Thank you very much.
Dr Robert J. Cerfolio (Birmingham, Ala). Excellent presenta-
tion. I have some questions about the technical details. We have
a paper coming out in the Journal of Thoracic and Cardiovascular
Surgery in a month or 2 months, I think, about 160 robotic medi-
astinal tumors, and a lot of them are thymectomies. I teach a course
on this issue and I tell everybody that you should go from the right
side, and the reason I prefer the right, and I don’t know if you can
go back to that picture of yours where you have the one thing just
under the left breast, is you’re very close to the heart, and in the
United States we know of at least 4 patients who had attempted ro-
botic thymectomies in inexperienced hands from the left side and
the heart was lacerated, the pericardium was injured, and a few of
these patients did not do well. So I feel strongly that we, especiallyThe Journal of Thoracic and Carin the beginning, should be going from the right side and not the
left. However, I do agree that you can see the right phrenic nerve
better from the left chest.
So it would be great if you could educate us on how you’re doing
it so safely from the left and maybe you can instill your experience
and wisdom to us sowhen we teach inexperienced teams how to do
it, we can do it safer from the left. You make the middle incision
first, correct? Then put the camera in, insufflate carbon dioxide,
you do that first. What port do you put in second? Do you put in
the upper axillary port second and then push the heart down as
you put in the third and final lower port?What do you do if the heart
is big and it’s in the way? Teach us some technical tricks.
Dr Marulli. Most patients were operated by the left-sided ap-
proach. Only 5 patients had a bilateral approach. We don’t feel
that it’s difficult to see the right phrenic nerve, because if you
open the pleura on the—
Dr Cerfolio. No, no. I understand you can see the right phrenic
nerve very easily from the left and there is often a tongue of thymus
near the aortopulmonary window that is much easier to get out
from the left rather than the right. That’s not my question. I agree
that is the advantage to being on the left. That’s not what I’m ask-
ing. What I’m asking is, there have been injuries to the heart being
on the left side, and as someone who is training others on this, and
we will be submitting a manuscript on this, even with a left-sided
thymoma, we are going on the right. I’m asking you to tell us how
you’re avoiding the heart with the sequence of your trocar place-
ment and other technical details to make it safe in inexperienced
hands. I want you to educate us on your technique because it seems
to be very safe in your hands and not in ours or others. That’s the
question.
DrMarulli.Wefirst insert the trocar for the camera port follow-
ing the lateral aspect of the chest wall to avoid the heart, then we
insufflate carbon dioxide, and usually this gives us enough space to
place the parasternal trocar without risks of heart injury. Some-
times, for more safety, we use the port at the spot on the third in-
tercostal space going over the heart and taking it down with
a cadiere or spatula. By this way, I think it’s not dangerous.
Dr Cerfolio. So you’re turning your carbon dioxide up, you’re
putting a spatula to hold the heart down, and then putting that port
in last, using a needle to find it. I’ve tried all those things. I still
think we should be on the right, at least to start. I think it’s safer
on the right.
Dr Wright. Let me just jump up and defend the poor author
here. He has an outstanding series of 80 patients with no heart in-
juries, Cerf. He’s doing it theway he likes to do it. We all know that
there’s a controversy of right versus left, and there’s pros and cons
to each approach, but I would say that his approach is certainly
valid.
Dr Cerfolio. I agree. I didn’t say it wasn’t. Maybe you didn’t
hear me, Cam.
Dr Shrager. He said, explain how you can best do it safely.
DrCerfolio. I am happy to have someone go back to read what I
just said. I never said their technique was not safe. We have
a unique opportunity for a world-class group to educate us in
this room right now. What I said is, I think it’s safer to be on the
right for training or to start, and I stand by what I say.
Dr Jens C. Rueckert (Berlin, Germany). I would like to add
a comment. With 280 thymectomies, we have had no difficultiesdiovascular Surgery c Volume 144, Number 5 1131
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Sever with the left-sided approach. The discussion here is, again,
well, I’ll take it home because then I see it’s right to publish on
that question alone. I prepared the manuscript, including all the ar-
guments I heard during the last 15 years, very interesting argu-
ments. I heard that the right-handed surgeon could be better
coming from the right side. Maybe. But the radicality is the most
important question, and the placement of the trocars should be
learned, of course, with insufflation of carbon dioxide in the older
or bigger patient, this is correct, but radicality is better from the left
side.We include always, even in patients without thymoma, a com-
plete resection, en bloc resection, of the tissue in the aortopulmo-
nary window. This is clearly better from the left side. And the
angulation of the typical anatomic site, the anatomic landmark of
the innominate, it’s better entering the neck from the left side. There
is much more to be said. If we discuss the right side for that ap-
proach, don’t leave the room without the message: the left side.
Dr Alper Toker (Istanbul, Turkey). I would like to know what
your attitude is toward lymph node dissection, especially in type C
patients.1132 The Journal of Thoracic and Cardiovascular SurDr Marulli. Obviously, in this case, the histology was known
only after the resection. So this patient was a surprise for us. In
this case, only adjuvant radiotherapy was considered for this pa-
tient. But intraoperatively, the patient had thymoma, apparently
encapsulated thymoma, so it was unknown. Usually for stage I
and stage II there is no need for lymphadenectomy.
Dr Shrager. Is there a size limit at which you would not ap-
proach a thymoma robotically? And for the audience: Is anybody
trying to do tumors that might be involving the great vessels
robotically?
Dr Marulli. The best indication is less than 3 cm. For robotic,
probably less than 5 cm.
Dr Shrager. But your mean size here was 3 cm.
Dr Marulli. Yes. We had 14 patients who had a dimension>5
cm. Only 1 was 12 cm. Most of the patients were<8 cm. If the
tumor is unilateral in the lower part of the thymus, probably resec-
tion can be safe with easy access to the contralateral mediastinum
and the neck. In these cases, you can do also a tumor>5 cm. A
good indication is less than 5 cm.gery c November 2012
